Gewinn- und Verlustrechnung von Moderna, Inc.

These stocks have all soared more than 350% this year.

Few large biotech stocks have rewarded patience like Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the size of that run now raises a hard question about what comes next. Moderna stock is up 545% year-to-date to $190.

All three major indexes are higher today, with the Nasdaq and S&P 500 scoring new record highs as bond yields cool off

Moderna, Inc. (NASDAQ: MRNA - Get Free Report) reached a new 52-week high during trading on Tuesday. The stock traded as high as $211.89 and last traded at $196.6480, with a volume of 2459099 shares traded. The stock had previously closed at $203.21. Analysts Set New Price Targets A number of research firms have recently weighed

A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low.

Sanofi is carrying the Nuvaxovid COVID-19 shot into the fall vaccination season, and buyers are rewarding shares of licensor Novavax (NASDAQ:NVAX) far more heavily than the rest of biotech. Novavax stock has rose 17% during afternoon trading, reaching $12.

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are trading as though the company's messenger RNA (mRNA) cancer vaccine has already cleared its final test, even though the complete Phase 3 dataset has yet to be presented publicly.

Stock futures are moving notably higher as investors digest nonfarm payrolls and cooling yields

Nike (NKE) faces persistent headwinds, with Q1 sales down 4% and China revenue plunging 22% year-over-year. Moderna (MRNA) will join the Nasdaq-100 replacing Warner Bros Discovery (WBD).

Moderna stock (NASDAQ: MRNA) rose more than 2% in early premarket trading on Friday after Nasdaq said the biotech company will join the Nasdaq-100 next week, creating new demand from index-tracking funds. The move follows a spectacular 2026 rally that has pushed Moderna more than 500% higher and transformed it from a post-pandemic recovery story into an oncology bet.